Thinking and acting beyond the positive: The role of the cognitive and negative symptoms in schizophrenia

CNS Spectrums

Volumn 19, Issue S1, 2014, Pages 38-52

  Carbon, Maren ^a   Correll, Christoph U ^a,b,c,d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Assessment; Cognition; Negative symptoms; Schizophrenia; Treatment

Indexed keywords

ACETYLCYSTEINE; ADX 71149; AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZOIC ACID; BITOPERTIN; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; GLUTAMATE TRANSPORTER INHIBITOR; GLYCINE; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PLACEBO; POMAGLUMETAD METHIONIL; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 3 AGONIST; SEROTONIN 6 ANTAGONIST; SERTINDOLE; SEX HORMONE; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ADVERSE DRUG REACTION; ALOGIA; ANHEDONIA; ANTICIPATORY ANHEDONIA; ANTISOCIAL BEHAVIOR; ANXIETY DISORDER; AUTONOMIC NERVOUS SYSTEM; AVOLITION; BIPOLAR DISORDER; BLUNTED AFFECT; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA; CAREGIVER BURDEN; CHOLINERGIC SYSTEM; CLINICAL ASSESSMENT INTERVIEW FOR NEGATIVE SYMPTOMS; CLINICAL COMPETENCE; CLINICAL GLOBAL IMPRESSION OF COGNITION IN SCHIZOPHRENIA; CLINICAL PRACTICE; COGNITIVE BEHAVIORAL THERAPY; COGNITIVE DEFECT; COGNITIVE REMEDIATION THERAPY; COMORBIDITY; COMPUTER ASSISTED THERAPY; CONSUMMATORY ANHEDONIA; CONVALESCENCE; DEMENTIA; DEPRESSION; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE BURDEN; DISEASE EXACERBATION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DSM-5; EXTRAPYRAMIDAL SYMPTOM; FUNCTIONAL DISEASE; GLOBAL ASSESSMENT OF FUNCTIONING; GLUTAMATERGIC SYSTEM; GOAL ATTAINMENT; HEALTH CARE NEED; HOPKINS VERBAL LEARNING TEST; HUMAN; LOW DRUG DOSE; MEASUREMENT AND TREATMENT RESEARCH TO IMPROVE COGNITION IN SCHIZOPHRENIA; MEMORY DISORDER; MENTAL DEFICIENCY; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; MOTIVATION; NEGATIVE SYMPTOM ASSESSMENT SCALE 16; NEGATIVE SYMPTOM ASSESSMENT SCALE 4; NEGATIVE SYNDROME; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PARANOIA; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PATIENT PARTICIPATION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PREVALENCE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PROGNOSIS; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RATING SCALE; RELIABILITY; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION; REVIEW; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCALE FOR THE ASSESSMENT OF POSITIVE SYMPTOMS; SCHIZOPHRENIA; SCHIZOPHRENIA COGNITION RATING SCALE; SEDATION; SENSITIVITY AND SPECIFICITY; SEROTONINERGIC SYSTEM; SOCIAL COMPETENCE; THE BRIEF NEGATIVE SYMPTOM SCALE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; APHASIA; COGNITION DISORDERS; COGNITIVE THERAPY; COMPLICATION; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGY;

ANHEDONIA; ANTIPSYCHOTIC AGENTS; APHASIA; COGNITION DISORDERS; COGNITIVE THERAPY; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84925229841     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852914000601     Document Type: Review

References (195)

1. Kirkpatrick B, Strauss GP, Nguyen L, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011; 37(2): 300-305.
2. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006; 32(2): 238-245.
3. Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry. 2013; 170(2): 165-172.
4. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 2010; 36(2): 359-369.
5. Pizzagalli DA. The "anhedonia paradox" in schizophrenia: insights from affective neuroscience. Biol Psychiatry. 2010; 67(10): 899-901.
6. Cohen AS, Minor KS. Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies. Schizophr Bull. 2010; 36(1): 143-150.
7. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007; 33(4): 1013-1022.
8. Kinon BJ, Noordsy DL, Liu-Seifert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol. 2006; 26(5): 453-461.
9. Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013; 150(2-3): 339-342.
10. Levine SZ, Leucht S. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. Schizophr Res. 2013; 145(1-3): 125-127.
11. Galderisi S, Maj M. Deficit schizophrenia: an overview of clinical, biological and treatment aspects. Eur Psychiatry. 2009; 24(8): 493-500.
12. Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011; 33(12): B16-39.
13. Kane JM. Tools to assess negative symptoms in schizophrenia. J Clin Psychiatry. 2013; 74(6): e12.
14. Selten JP, Wiersma D, van den Bosch RJ. Discrepancy between subjective and objective ratings for negative symptoms. J Psychiatr Res. 2000; 34(1): 11-13.
15. Marder SR, Alphs L, Anghelescu IG, et al. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res. 2013; 150(2-3): 328-333.
16. Alphs L, Summerfelt A, Lann H, Muller RJ. The Negative Symptom Assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull. 1989; 25(2): 159-163.
17. Alphs L, Morlock R, Coon C, Cazorla P, Szegedi A, Panagides J. Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia. Int J Methods Psychiatr Res. 2011; 20(2): e31-37.
18. Forbes C, Blanchard JJ, Bennett M, Horan WP, Kring A, Gur R. Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr Res. 2010; 124(1-3): 36-42.
19. Strauss GP, KellerWR, Buchanan RW, et al. Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res. 2012; 142(1-3): 88-92.
20. Bobes J, Arango C, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010; 71(3): 280-286.
21. Strauss GP, Horan WP, Kirkpatrick B, Fischer BA, KellerWR,Miski P, Buchanan RW, Green MF, Carpenter WT Jr. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res. 2013; 47(6): 783-90.
22. Peralta V, CuestaMJ. Dimensional structure of psychotic symptoms: an item-level analysis of SAPS and SANS symptoms in psychotic disorders. Schizophr Res. 1999; 38(1): 13-26.
23. Lyne J, O'Donoghue B, Owens E, et al. Prevalence of item level negative symptoms in first episode psychosis diagnoses. Schizophr Res. 2012; 135(1-3): 128-133.
24. Fulford D, Niendam TA, Floyd EG, et al. Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms. Schizophr Res. 2013; 147(1): 125-131.
25. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a comprehensive state-of-The-art review. JAMA Psychiatry. 2013; 70(1): 107-120.
26. Üçok A, Ergül C. Persistent negative symptoms after first episode schizophrenia: a 2-year follow-up study. Schizophr Res. 2014; 158(1-3): 241-246.
27. Thorup A, Albert N, Bertelsen M, et al. Gender differences in firstepisode psychosis at 5-year follow-up-two different courses of disease? Results from the OPUS study at 5-year follow-up. Eur Psychiatry. 2014; 29(1): 44-51.
28. Nordon C, Rouillon F, Azorin JM, Barry C, Urbach M, Falissard B. Trajectories of antipsychotic response in drug-naive schizophrenia patients: results from the 6-month ESPASS follow-up study. Acta Psychiatr Scand. 2014; 129(2): 116-125.
29. Gaebel W, Riesbeck M, Wölwer W, et al. Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment: results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophr Res. 2014; 152(2-3): 478-486.
30. Fervaha G, Foussias G, Agid O, Remington G. Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur Psychiatry. 2014; 29(7): 449-455.
31. Verma S, Subramaniam M, Abdin E, Poon LY, Chong SA. Symptomatic and functional remission in patients with first-episode psychosis. Acta Psychiatr Scand. 2012; 126(4): 282-289.
32. Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. In press.
33. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000; 157(4): 549-559.
34. Gold JM,Weinberger DR. Cognitive deficits and the neurobiology of schizophrenia. Curr Opin Neurobiol. 1995; 5(2): 225-230.
35. Javitt DC, Doneshka P, Grochowski S, Ritter W. Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia.ArchGen Psychiatry. 1995; 52(7): 550-558.
36. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004; 56(5): 301-307.
37. Fusar-Poli P, Deste G, Smieskova R, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 2012; 69(6): 562-571.
38. Brewer WJ, Wood SJ, Phillips LJ, et al. Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr Bull. 2006; 32(3): 538-555.
39. Bora E, Lin A, Wood SJ, Yung AR, McGorry PD, Pantelis C. Cognitive deficits in youth with familial and clinical high risk to psychosis: a systematic review and meta-analysis. Acta Psychiatr Scand. 2014; 130(1): 1-15.
40. Olvet DM, Burdick KE, Cornblatt BA. Assessing the potential to use neurocognition to predict who is at risk for developing bipolar disorder: a review of the literature. Cogn Neuropsychiatry. 2013; 18(1-2): 129-145.
41. Galderisi S, Davidson M, Kahn RS, et al; EUFEST group. Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. Schizophr Res. 2009; 115(2-3): 104-114.
42. Fatouros-Bergman H, Cervenka S, Flyckt L, Edman G, Farde L. Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia. Schizophr Res. 2014; 158(1-3): 156-162.
43. Bora E, Murray RM. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull. 2014; 40(4): 744-755.
44. Andreasen NC, Rezai K, Alliger R, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry. 1992; 49(12): 943-958.
45. Bozikas VP, Kosmidis MH, Kioperlidou K, Karavatos A. Relationship between psychopathology and cognitive functioning in schizophrenia. Compr Psychiatry. 2004; 45(5): 392-400.
46. Buchanan RW, Strauss ME, Breier A, Kirkpatrick B, CarpenterWT Jr. Attentional impairments in deficit and nondeficit forms of schizophrenia. Am J Psychiatry. 1997; 154(3): 363-370.
47. Hughes C, Kumari V, Soni W, et al. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res. 2003; 59(2-3): 137-146.
48. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006; 31(9): 2033-2046.
49. Sponheim SR, Jung RE, Seidman LJ, et al. Cognitive deficits in recent-onset and chronic schizophrenia. J Psychiatr Res. 2010; 44(7): 421-428.
50. Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust N Z J Psychiatry. 2011; 45(2): 93-108.
51. Barder HE, Sundet K, Rund BR, et al. Ten year neurocognitive trajectories in first-episode psychosis. Front Hum Neurosci. 2013; 7: 643.
52. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a metaanalytic review. Neuropsychology. 2009; 23(3): 315-336.
53. Sitskoorn MM, Aleman A, Ebisch SJ, Appels MC, Kahn RS. Cognitive deficits in relatives of patients with schizophrenia: a metaanalysis. Schizophr Res. 2004; 71(2-3): 285-295.
54. Dickerson F, Boronow JJ, Stallings C, Origoni AE, Cole SK, Yolken RH. Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status. Psychiatry Res. 2004; 129(1): 45-53.
55. Krabbendam L, Arts B, Van Os J, Aleman A. Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophr Res. 2005; 80(2-3): 137-149.
56. Bora E, Yucel M, Pantelis C. Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: metaanalytic study. Br J Psychiatry. 2009; 195(6): 475-482.
57. Pantelis C, Stuart GW, Nelson HE, Robbins TW, Barnes TRE. Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms. Am J Psychiatry. 2001; 158(8): 1276-1285.
58. Keefe RS. Should cognitive impairment be included in the diagnostic criteria for schizophrenia?World Psychiatry. 2008; 7(1): 22-28.
59. Brandt J, Benedict R. Hopkins Verbal Learning Test. Lutz, FL: Psychological Assessment Resources; 1991.
60. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998; 20(3): 310-319.
61. Loughland CM, Lewin TJ, Carr VJ, Sheedy J, Harris AW. RBANS neuropsychological profiles within schizophrenia samples recruited from non-clinical settings. Schizophr Res. 2007; 89(1-3): 232-242.
62. Chianetta JM, Lefebvre M, LeBlanc R, Grignon S. Comparative psychometric properties of the BACS and RBANS in patients with schizophrenia and schizoaffective disorder. Schizophr Res. 2008; 105(1-3): 86-94.
63. Ehrenreich H, Hinze-Selch D, Stawicki S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry. 2007; 12(2): 206-220.
64. Fenton WS, Dickerson F, Boronow JJ, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001; 158(12): 2071-2074.
65. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006; 63(6): 630-638.
66. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004; 72(1): 29-39.
67. Pantelis C, Barnes TR, Nelson HE, et al. Frontal-striatal cognitive deficits in patients with chronic schizophrenia. Brain. 1997; 120(Pt 10): 1823-1843.
68. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004; 68(2-3): 283-297.
69. Caletti E, Paoli RA, Fiorentini A, et al. Neuropsychology, social cognition and global functioning among bipolar, schizophrenic patients and healthy controls: preliminary data. Front Hum Neurosci. 2013; 7: 661.
70. Kaneda A, Katagai T, Yasui-Furukori N. Comparing the influences of age and disease on the Brief Assessment of Cognition in Schizophrenia in Japanese patients with schizophrenia. Neuropsychiatr Dis Treat. 2013; 9: 1203-1208.
71. Hill SK, Reilly JL, Keefe RS, et al. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry. 2013; 170(11): 1275-1284.
72. Hill SK, Sweeney JA, Hamer RM, et al. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. J Int Neuropsychol Soc. 2008; 14(2): 209-221.
73. Sellwood W, Morrison AP, Beck R, Heffernan S, Law H, Bentall RP. Subjective cognitive complaints in schizophrenia: relation to antipsychotic medication dose, actual cognitive performance, insight and symptoms. PLoS One. 2013; 8(12): e83774.
74. Suzuki H, Gen K, Inoue Y, et al. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. Int J Psychiatry Clin Pract. 2014; 18(1): 58-62.
75. Wang HL, Xiang YT, Li QY, et al. The effect of artemether on psychotic symptoms and cognitive impairment in first-episode, antipsychotic drug-naive persons with schizophrenia seropositive to Toxoplasma gondii. J Psychiatr Res. 2014; 53: 119-124.
76. Buchanan RW, Davis M, Goff D, et al. A summary of the FDANIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005; 31 (1): 5-19.
77. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull. 2011; 37(6): 1209-1217.
78. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008; 165(2): 203-213.
79. Kern RS, Gold JM, Dickinson D, et al. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res. 2011; 126(1-3): 124-131.
80. Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res. 2011; 125(2-3): 161-168.
81. Jarskog LF, Dong Z, Kangarlu A, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology. 2013; 38(7): 1245-1252.
82. Weiser M, Heresco-Levy J, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012; 73: e728-34.
83. Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry. 2006; 163(3): 426-432.
84. Poletti S, Anselmetti S, Riccaboni R, et al. Self-awareness of cognitive functioning in schizophrenia: patients and their relatives. Psychiatry Res. 2012; 198(2): 207-211.
85. Vita A, Deste G, Barlati S, et al. Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. Schizophr Res. 2013; 146(1-3): 217-223.
86. Harvey PD, OgasaM, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011; 127(1-3): 188-194.
87. Bora E, Yücel M, Pantelis C. Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond. Schizophr Bull. 2010; 36(1): 36-42.
88. Palmer BW, Heaton RK, Paulsen JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology. 1997; 11(3): 437-446.
89. Keefe RSE, Eesley CE, Poe M. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry. 2005; 57(6): 688-691.
90. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996; 153(3): 321-330.
91. Evans JD, Heaton RK, Paulsen JS, Palmer BW, Patterson T, Jeste DV. The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenic patients. Biol Psychiatry. 2003; 53(5): 422-430.
92. Gold S, Arndt S, Nopoulos P, O'Leary DS, Andreasen NC. Longitudinal study of cognitive function in first-episode and recentonset schizophrenia. Am J Psychiatry. 1999; 156(9): 1342-1348.
93. Jordan G, Lutgens D, Joober R, Lepage M, Iyer S, Malla A. The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J Clin Psychiatry. 2014; 75(6): e566-e572.
94. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year followup. Am J Psychiatry. 2005; 162(3): 495-506.
95. Stirling J, White C, Lewis S, et al. Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr Res. 2003; 65(2-3): 75-86.
96. Rajji TK, Miranda D, Mulsant BH. Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies. Can J Psychiatry. 2014; 59(1): 13-17.
97. Allott K, Liu P, Proffitt TM, Killackey E. Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. Schizophr Res. 2011; 125(2-3): 221-235.
98. Ventura J, Cienfuegos A, Boxer O, Bilder R. Clinical Global Impression of Cognition in Schizophrenia (CGI-CogS): reliability and validity of a co-primary measure of cognition. Schizophr Res. 2008; 106(1): 59-69.
99. Ventura J, Reise SP, Keefe RS, et al. The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. Schizophr Res. 2010; 121(1-3): 24-31.
100. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry. 2006; 163(3): 418-425.
101. Fervaha G, Zakzanis KK, Foussias G, Graff-Guerrero A, Agid O, Remington G. Motivational deficits and cognitive test performance in schizophrenia. JAMA Psychiatry. 2014; 71(9): 1058-1065.
102. Fervaha G, Foussias G, Agid O, Remington G. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr Scand. 2014; 130(4): 290-299.
103. Schmidt SJ, Mueller DR, Roder V. Social cognition as a mediator variable between neurocognition and functional outcome in schizophrenia: empirical review and new results by structural equation modeling. Schizophr Bull. 2011; 37(Suppl 2): S41-54.
104. Nakagami E, Xie B, Hoe M, Brekke JS. Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophr Res. 2008; 105(1-3): 95-104.
105. Keshavan MS, Vinogradov S, Rumsey J, Sherrill J, Wagner A. Cognitive training in mental disorders: update and future directions. Am J Psychiatry. 2014; 171(5): 510-522.
106. Grant PM, Huh GA, Perivoliotis D, Stolar NM, Beck AT. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry. 2012; 69(2): 121-127.
107. Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry. 2014; 204(1): 20-29.
108. Dixon LB, Dickerson F, Bellack AS, et al. Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010; 36(1): 48-70.
109. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008; 34(3): 523-537.
110. Elis O, Caponigro JM, Kring AM. Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions. Clin Psychol Rev. 2013; 33(8): 914-928.
111. Klingberg S, Wölwer W, Engel C, et al. Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. Schizophr Bull. 2011; 37(Suppl 2): S98-110.
112. Medalia A, Saperstein AM. Does cognitive remediation for schizophrenia improve functional outcomes? Curr Opin Psychiatry. 2013; 26(2): 151-157.
113. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A metaanalysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011; 168(5): 472-485.
114. Puig O, Penadés R, Baeza I, et al. Cognitive remediation therapy in adolescents with early-onset schizophrenia: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2014; 53(8): 859-868.
115. Trapp W, Landgrebe M, Hoesl K, et al. Cognitive remediation improves cognition and good cognitive performance increases time to relapse-results of a 5 year catamnestic study in schizophrenia patients. BMC Psychiatry. 2013; 13: 184.
116. Liberman RP, Wallace CJ, Blackwell G, Kopelowicz A, Vaccaro JV, Mintz J. Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia. Am J Psychiatry. 1998; 155(8): 1087-1091.
117. Rus-Calafell M, Gutiérrez-Maldonado J, Ortega-Bravo M, Ribas-Sabaté J, Caqueo-Urízar A. A brief cognitive-behavioural social skills training for stabilised outpatients with schizophrenia: a preliminary study. Schizophr Res. 2013; 143(2-3): 327-336.
118. Nordentoft M, Melau M, Iversen T, et al. From research to practice: how OPUS treatment was accepted and implemented throughout Denmark. Early Interv Psychiatry. In press. DOI: 10.1111/eip.12108.
119. Dickinson D, Tenhula W, Morris S, et al. A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Am J Psychiatry. 2010; 167(2): 170-180.
120. Grynszpan O, Perbal S, Pelissolo A, et al. Efficacy and specificity of computer-assisted cognitive remediation in schizophrenia: a metaanalytical study. Psychol Med. 2011; 41(1): 163-173.
121. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014; 24(5): 645-692.
122. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009; 166(2): 152-163.
123. Fervaha G, Foussias G, Agid O, Remington G. Neural substrates underlying effort computation in schizophrenia. Neurosci Biobehav Rev. 2013; 37(10 Pt 2): 2649-2665.
124. Padmanabhan JL, Tandon N, Haller CS, et al. Correlations between brain structure and symptom dimensions of psychosis in schizophrenia, schizoaffective, and psychotic bipolar I disorders. Schizophr Bull. In press. DOI: 10.1093/schbul/sbu075.
125. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014; 24(5): 645-692.
126. Köster LS, Carbon M, Correll CU. Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs. 2014; 19: 1-21. [Epub ahead of print] PMID: 25234340.
127. Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry. 1999; 4(5): 418-428.
128. Millan MJ. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl). 2005; 179(1): 30-53.
129. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002; 159(2): 180-190.
130. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006; 163(4): 600-610.
131. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006; 163(4): 611-622.
132. Souza JS, Kayo M, Tassell I, Martins CB, Elkis H. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and metaanalyses. CNS Spectr. 2013; 18(2): 82-89.
133. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009; 166(2): 152-163.
134. Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 187(3): 312-320.
135. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011; 127(1-3): 188-194.
136. Keefe RS, Bilder RM, Davis SM, et al; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007; 64(6): 633-647.
137. Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev. 2006; (3): CD005581.
138. Sepehry AA, Potvin S, Elie R, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: ameta-analysis. J Clin Psychiatry. 2007; 68(4): 604-610.
139. Singh SP, Singh V, Kar N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: metaanalysis. Br J Psychiatry. 2010; 197(3): 174-179.
140. Kishi T, Meltzer HY, Iwata N. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a metaanalysis. Int J Neuropsychopharmacol. 2013; 16(6): 1259-1266.
141. Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, doubleblind, placebo-controlled study. Schizophr Res. 2007; 95(1-3): 158-168.
142. Sumiyoshi T, Matsui M, Yamashita I, et al. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry. 2001; 49(10): 861-868.
143. Akhondzadeh S, Mohammadi N, Noroozian M, et al. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res. 2009; 107(2-3): 206-212.
144. Zhang XY, Liu L, Liu S, et al. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry. 2012; 169(9): 974-981.
145. Morozova MA, Beniashvili AG, Lepilkina TA, Rupchev GE. Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. Psychiatr Danub. 2012; 24(2): 159-166.
146. Vernon JA, Grudnikoff E, Seidman AJ, et al. Antidepressants for cognitive symptoms in schizophrenia-a systematic review and meta-analysis. Schizophr Res. In press. doi;10.1016/ j.schres.2014.08.015.
147. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev. 2006; (2): CD003730. Review. PubMed PMID:16625590.
148. Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007; 164(10): 1593-1602.
149. Goff DC, Cather C, Gottlieb JD, et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res. 2008; 106(2-3): 320-327.
150. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007; 13(9): 1102-1107.
151. Stauffer VL, Millen BA, Andersen S, et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res. 2013; 150(2-3): 434-441.
152. Addex Web Page. Press release: Addex reports top-line data from a successful phase 2a clinical study with ADX71149 in schizophrenia patients. November 5, 2012. http://www.addextherapeutics.com/ investors/press-releases/news-details/article/addex-reports-topline-data-from-a-successful-phase-2a-clinical-study-withadx71149-in-schizophrenia.
153. Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008; 33(9): 2187-2199.
154. Kantrowitz JT,Malhotra AK, Cornblatt B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 2010; 121(1-3): 125-130.
155. Lane HY, Chang YC, Liu YC, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005; 62(11): 1196-1204.
156. Pinard E, Alanine A, Alberati D, et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl) piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy) phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem. 2010; 53(12): 4603-4614.
157. Umbricht D, Alberati D, Martin-Facklam M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014; 71(6): 637-646.
158. Ferraris DV, Tsukamoto T. Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia. Curr Pharm Des. 2011; 17(2): 103-111.
159. Lane HY, Lin CH, Green MF, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013; 70(12): 1267-1275.
160. Hashimoto K,Malchow B, Falkai P, Schmitt A. Glutamatemodulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci. 2013; 263(5): 367-377.
161. Jones CK, Byun N, Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology. 2012; 37(1): 16-42.
162. Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008; 165(8): 1033-1039.
163. Lee BJ, Lee JG, Kim YH. A 12-week, double-blind, placebocontrolled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J Psychopharmacol. 2007; 21(4): 421-427.
164. Lee SW, Lee JG, Lee BJ, Kim YH. A 12-week, double-blind, placebocontrolled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol. 2007; 22(2): 63-68.
165. Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry. 2006; 60(6): 530-533.
166. Stip E, Sepehry AA, Chouinard S. Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2. Clin Neuropharmacol. 2007; 30(4): 218-229.
167. Chouinard S, Sepehry AA, Stip E. Oral cholinesterase inhibitor addon therapy for cognitive enhancement in schizophrenia: a quantitative systematic review, part I. Clin Neuropharmacol. 2007; 30(3): 169-182.
168. Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry. 2003; 60(2): 133-141.
169. Strous RD, Stryjer R, Maayan R, et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology. 2007; 32(2): 96-105.
170. Ko YH, Lew YM, Jung SW, et al. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008; 28(4): 375-383.
171. Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychopharmacol. 2006; 26(5): 495-499.
172. Begemann MJ, Dekker CF, van Lunenburg M, Sommer IE. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res. 2012; 141(2-3): 179-184.
173. Ritsner MS, Gibel A, Shleifer T, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, doubleblind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry. 2010; 71(10): 1351-1362.
174. Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res. 2005; 77(1): 43-58.
175. Lindenmayer JP, Nasrallah H, Pucci M, James S, Citrome L. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr Res. 2013; 147(2-3): 241-252.
176. Lasser RA, Dirks B, Nasrallah H, et al. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases. Neuropsychopharmacology. 2013; 38(11): 2140-2149.
177. Bobo WV, Woodward ND, Sim MY, Jayathilake K, Meltzer HY. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2011; 130(1-3): 106-113.
178. Kane JM, Yang R, Youakim JM. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebocontrolled study. Schizophr Res. 2012; 135(1-3): 116-122.
179. Lohr JB, Liu L, Caligiuri MP, et al. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebocontrolled study. Schizophr Res. 2013; 150(1): 289-296.
180. Lefaucheur JP, André-Obadia N, Antal A, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. In press. DOI: 10.1016/j.clinph.2014.05.021.
181. Shi C, Yu X, Cheung EF, Shum DH, Chan RC. Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis. Psychiatry Res. 2014; 215(3): 505-513.
182. Liu F, Guo X, Wu R, et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014; 153(1-3): 169-176.
183. Berk M, Copolov D, Dean O, et al. N-Acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008; 64(5): 361-368.
184. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261-276.
185. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997; 58(12): 538-546.
186. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl. 1989; 7: 49-58.
187. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item Negative Symptom Assessment. J PsychiatrRes. 1993; 27(3): 253-258.
188. Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 2009; 31(7): 848-859.
189. Wilk CM, Gold JM, Bartko JJ, et al. Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry. 2002; 159(5): 838-844.
190. Hurford IM, Marder SR, Keefe RS, Reise SP, Bilder RM. A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull. 2011; 37(3): 538-545.
191. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007; 64(5): 532-542.
192. Wu C, Dagg P, Molgat C. A pilot study to measure cognitive impairment in patients with severe schizophrenia with the Montreal Cognitive Assessment (MoCA). Schizophr Res. 2014; 158(1-3): 151-155.
193. Nasreddine Z. The Montreal Cognitive Assessment. http://www. mocatest.org.
194. Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior rating inventory of executive function. Child Neuropsychol. 2000; 6(3): 235-238.
195. Opler M, Antonius D, Correll CU. New York Assessment of Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT). Unpublished rating instrument.